Eloralintide
Eloralintide is an experimental once-weekly injection from Eli Lilly that acts on the amylin receptor, a different target from the GLP-1 drugs. A mid-stage trial showed weight loss of up to about 20%. It is in Phase 3 trials and cannot be prescribed.
- Legal lane: investigational. Not FDA-approved and not available by prescription.
- Evidence grade: B. One strong mid-stage trial; Phase 3 results not yet in.
- Form: weekly injection under the skin
- Developer: Eli Lilly
What it is
Amylin is a hormone released with insulin that helps produce the feeling of fullness. Eloralintide is a selective amylin receptor agonist, formerly known as LY3841136. It belongs to the same new class as cagrilintide.
What the evidence shows
The Phase 2 trial enrolled 263 adults with obesity, or overweight with a related condition, and without type 2 diabetes. At 48 weeks, average weight loss ranged from 9.5% on the lowest dose to 20.1% on the highest, against 0.4% on placebo. Lilly presented the results in November 2025.
In September 2026 Lilly reported that eloralintide combined with tirzepatide produced more weight loss than tirzepatide alone in a 48-week trial in adults with obesity and type 2 diabetes.
These are company-reported mid-stage results. Phase 3 trials, which are larger and longer, decide whether the effect and the safety hold up.
Legal status
- Not FDA-approved. Phase 3 trials of eloralintide alone are under way.
- Lilly said it would start Phase 3 trials of the combination with tirzepatide in the last quarter of 2026.
- The only lawful way to receive it is as a participant in a trial. Anything sold online under this name has no regulated source.
Reported dosing
No approved dose exists.
The Phase 2 trial tested 1 mg, 3 mg, 6 mg and 9 mg once a week, and two schedules that stepped up to 9 mg. Those are trial doses in a monitored study, not a recommendation.
Safety
- Lilly described the tolerability as favorable in Phase 2. Full safety data will come from Phase 3.
- Long-term safety is unknown.
- Products sold as eloralintide outside a trial have no verified contents.
Common questions
Is eloralintide FDA-approved?
No. It is in Phase 3 trials.
How much weight did people lose on eloralintide?
Between 9.5% and 20.1% at 48 weeks in the Phase 2 trial, depending on dose, against 0.4% on placebo.
How is eloralintide different from a GLP-1?
It acts on the amylin receptor, a separate fullness signal.
Can I get eloralintide now?
Only by taking part in a clinical trial.
Ask an AI about this page
Opens the assistant with a question about this page already typed in. You can edit it before sending.
Ask ChatGPTAsk ClaudeAsk Perplexity
These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.